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Abstract
Serotonin (5-HT) is a neurotransmitter that has important functions such as the 
physiological regulation of hemostasis, blood clotting, bone metabolism, cardiovas-
cular growth, contractile activity and gastrointestinal motility, renal function, and 
stress and sexual behavior, among others. In this review, we consider the potential 
of 5-HT to contribute to the development of various pathological conditions, 
including metabolic, vascular, and nervous disorders in horses. The values of 5-HT 
in circulation are modified under common pathological conditions. Thus, laminitis, 
endotoxemia, surgical cramps, recurrent airway obstruction, Cushing’s syndrome, 
central fatigue, and certain behavioral alterations such as stereotypes and other 
acute or chronic conditions can cause increased levels of 5-HT.
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1. Introduction
Serotonin (5-hydroxytryptamine, 5-HT) is an important neurocrine messenger 
that is synthesized from tryptophan (TRP) by tryptophan hydroxilase in the brain 
and mastocytes and enterochromaffin (EC) cells in the gastrointestinal (GI) tract 
[1]. TRP is able to cross the blood-brain barrier and metabolize into 5-HT in the 
raphe nuclei within the brain stem. In the intestinal tract, 5-HT is produced by EC 
and to a lesser extent by serotonergic neurons and released upon mucosal stimula-
tion. The synthesis of 5-HT is identical in the central nervous system (CNS) and in 
the gut, where TRP is first converted to 5-hydroxytryptophan (5-HTP) via trypto-
phan hydroxylase (TPH), the rate-limiting enzyme in the biosynthesis of enzyme. 
5-HT is eliminated from the interstitium by 5-HT transporters on enterocytes 
and neurons; 5-HT overflow from the gut reaches the intestinal lumen and portal 
circulation. In the circulation, it is quickly removed from the plasma by uptake into 
platelets (PLTs) or metabolized by monoamine oxidase (MAO) into 5-hydroxy-
indoleacetic acid (5-HIAA) in hepatic and lung endothelial cells. Plasma 5-HT is 
quickly transported into the PLTs via 5-HT reuptake transporter (5-HT transporter; 
SERT) on the PLT membrane. PLTs accumulate, store, and release 5-HT in an analo-
gous manner to central serotoninergic synaptosomes. The free plasma 5-HT exerts 
important systemic functions, modulating PLT aggregation, and has been reported 
to be also involved in vasomotor function [1, 2].
In GI tract, 5-HT interacts with receptors on afferent neurons, initiating peri-
staltic, secretion, and secretory reflexes. On the other hand, 5-HT induces smooth 
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muscle cell contraction and proliferation but stimulates endothelial cells to release 
vasodilating substances and acts as a “helper agonist” of PLT aggregation [2, 3].
Measurement of 5-HT in whole blood gives a reasonable approximation of 5-HT 
in PLTs [4], and the free 5-HT/whole blood-5-HT (f-5HT/WB-5-HT) ratio may be a 
marker of PLT activation [5]. The concentration of free 5-HT is typically measured 
in PLT-poor plasma (PPP), produced by prolonged or high-speed centrifugation of 
plasma and containing <10,000 PLTs/μl [6]. Several researchers reported PPP 5-HT 
values in healthy horses range from 2.5 ng/ml to 90 ng/ml, with a majority varying 
between 3 ng/ml and 30 ng/ml [7–16]. Plasma 5-HT is the fraction which shows the 
equilibrium state between synthesis by EC cells, the inactivation by liver and lung 
by MAO and PLT uptake.
5-HT plasma concentrations in horses are subject to physiological variations 
such as age [17, 18], exercise [7–9], stress [19], seasonal, circadian and nycthemeral 
rhythms [15, 20], altitude [21], reproductive status [22], and type of anticoagulant 
and laboratory technique [23–25]. In addition, these factors also influence the 
analytical results of this neurotransmitter. Even in healthy horses, reported refer-
ence values for 5-HT are not consistent, which hampers further research into the 
role of 5-HT in equine diseases. One possible explanation for this inconsistency is 
the use of different biological samples and analytical methods for 5-HT determina-
tion. Indeed, to determine the concentrations of 5-HT in whole blood high-pressure 
liquid chromatography (HPLC) [7] and in serum, commercially available enzyme-
linked immunosorbent assays (ELISA) or radioimmunoassays (RIAs) [19] have 
been used. Torfs et al. [24] showed that for accurate determination of plasma levels 
of 5-HT, it is essential to use PPP. It is believed that 5-HT in PPP reflects the amount 
of 5-HT synthesized and recently secreted in EC cells. Although ELISA [23] and 
HPLC [18, 21] have been used, the tandem chromatographic mass spectrometry 
(LC-MS/MS) method is suitable for determining the plasma reference values of 
5-HT and analyzing changes in 5-HT associated with pathological conditions.
2. Role of serotonin in the equine clinic
In horses, changes in 5-HT levels are associated with gastrointestinal pathologies 
such as ileus, colic or endotoxemia, vascular dysfunctions such as digital hypoper-
fusion causing laminitis, recurrent airway obstruction and endocrine disruption 
such as intermediate equine pituitary dysfunction (PPID) or Cushing syndrome, 
and behavioral alterations such as stereotypes [26, 27].
2.1 Gastrointestinal diseases: ileus, colic, and endotoxemia
In the intestine, there are three types of cells that produce 5-HT, such as immune 
cells, nerve cells and EC cells [26]. Free plasma 5-HT concentration is a potential 
predictive parameter for postoperative ileus, since it may reflect intestinal integrity, 
as well as the circulatory effects associated with inflammation or endotoxemia. 
Therefore, 5-HT quantitation might be an aid in prognosticating the outcome in 
horses with postoperative colic. The knowledge of plasma 5-HT changes in colic 
horses is also important in the quest for an effective treatment for ileus, since 
certain classes of prokinetic drugs target 5-HT receptors [26]. A risk of receptor 
desensitization [27] might exist when these drugs are used in patients with already 
elevated 5-HT levels.
5-HT contractile receptors have been identified in the longitudinal and circular 
layers of the smooth muscle [28] and myenteric neurons of descending colon, ileum 
and submucosal neurons of ileum, and duodenum in horses [29, 30], in which 5-HT 
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exerts local actions, causing the activation of intrinsic and extrinsic afferent neu-
rons. This initiates secretory and peristaltic responses to transmit the information to 
the CNS [27]. While the interaction of 5-HT with 5-HT2, 5-HT3, and 5-HT4 receptors 
stimulates contractibility, 5-HT1 and 5-HT7 receptors induce relaxing effects in the 
GI tract [31]. Among these types of receptors, 5-HT4 exerts important control over 
intestinal motility. Indeed, a prokinetic effect occurs following the administration 
of 5-HT4 agonists, such as Tegaserod and Mosapride [32].
In horses with intestinal hypomotility, the agonist of 5-HT4 receptor 
Prucalopride can increase motor contractility of the duodenum, cecum, and colon, 
30–90 minutes after oral administration. This motor activity is maximal in the 
duodenum, with a minimal increase in the cecum and left colon related with other 
intestinal segments [33]. Tegaserod is other selective agonist of 5-HT4 receptor 
that induces increase in the frequency and amplitude of contractions in equine 
ileum and pelvic flexion [34], speeding up GI transit time and increases frequency 
of bowel sounds and defecation [29]. In this way, Tegaserod can offer therapeutic 
potential in horses suffering from impaction or paralytic ileus. Cisapride is an 
indirect cholinergic prokinetic agent that acts by promoting the release of acetyl-
choline from intramural nerve terminals (myenteric plexus) through stimulation 
of 5-HT4 receptors [35]. Mosapride is other selective agonist of 5-HT4 receptors. 
The use of this agonist improves gastric, jejunal, and cecal motility in horses [36]. 
A disadvantage of this medication is the oral administration route. This complicates 
the use in horses with postoperative ileus. Unfortunately, the availability of this 
drug is also limited. On the other hand, Tegaserod with a higher risk of cardiac 
events in humans has been suspected (as for cisapride), its availability is limited, 
as well as its application in equine practice, explaining the lack of more clinical 
reports. This drug is a potent dopamine D2 receptor antagonist, a moderate 5-HT3 
receptor antagonist, and 5-HT4 receptor agonist [29] that increases the contractility 
of smooth muscle [37] and improved in vivo motility of the jejunum [36].
The final effects of 5-HT in the intestine will depend on plasma concentrations 
and the balance between activation and desensitization of these receptors. The 
concentrations of 5-HT in the intestinal mucous membrane and its association with 
postoperative bowel recovery may better reflect the net effects of 5-HT on intestinal 
motility [38].
5-HT is a very potent proinflammatory, vasoconstrictor, and immunomodula-
tory agent. Although Delesalle et al. [11] reported an increase in plasma concentra-
tions of 5-HT in horses with intestinal strangulation, Ayala et al. [19] showed a 
decrease in serum concentration of 5-HT in horses with acute abdominal pain.
Several authors have observed higher concentrations of 5-HT after ischemia-
reperfusion in the peritoneal fluid intestinal lumen and mesenteric, portal, and 
hepatic veins [11, 39]. Increased plasma of 5-HT can have important consequences 
in colic horses. It has been shown in vitro and in vivo that 5-HT is an important and 
very powerful vasoconstrictor agent [16]. The accumulation of 5-HT in the systemic 
circulation of horses that have colic may reinforce continuous intestinal ischemia. 
Both local lesions in the intestinal wall and the associated inflammatory and endo-
toxemic systemic reactions promote the development of ileus. The concentration 
of free 5-HT in plasma is a possible predictive parameter in cases of postoperative 
ileus, as it may reflect the integrity of the intestine, as well as the circulatory effects 
associated with inflammation or endotoxemia. For this reason, the quantification 
of 5-HT in horses could be an important tool to predict postsurgical evolution as a 
consequence of colic [26, 40].
Coagulation of circulating PLTs, as well as EC from necrotizing intestinal 
segments, could serve as a source of 5-HT. In horses, it is argued that intestinal 
ischemia makes the mucosa more permeable. This event leads to an important 
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translocation of endotoxins and amines from the diet, among which 5-HT passes 
from intestinal contents to systemic circulation [28]. Indeed, Davis et al. [41] 
showed liver lesions in horses suffering from proximal duodenitis-jejunitis. In 
addition to the lesion caused by the ascending bile duct infection, these authors 
also propose the absorption of endotoxins or inflammatory mediators of portal 
circulation. In addition, hepatic hypoxia resulting from systemic inflammation and 
endotoxemic shock may be possible causes of liver injury.
Intestinal microorganisms are also important for the 5-HT synthesis. Yano 
et al. [42] estimated that 90% of peripheral 5-HT is produced by the intestinal 
microbiota. These authors found that in germ-free mice, the production of 5-HT 
was approximately 60% less in comparison to mice with normal intestinal bacteria. 
Indeed, when bacterial colonies were restored in the intestines of germ-free mice, 
5-HT levels are recovered. Several metabolic byproducts of the intestinal microbiota 
are controlled by the mixture of spore-forming bacteria acting on EC to alter 5-HT 
production. However, bacteria are capable to produce 5-HT on their own. In fact, 
Lactobacillus spp. produce acetylcholine and GABA; Bifidobacterium spp. produce 
GABA, Escherichia produce norepinephrine, 5-HT, and dopamine; and Streptococcus 
and Enterococcus produce 5-HT. Bacillus species have also been shown to produce 
norepinephrine and dopamine [43].
Torfs et al. [24] showed that the plasma concentrations of 5-HT are significantly 
lower in horses with small bowel surgical colic compared to healthy animals. In 
addition, it was demonstrated that 5-HT concentrations remained low until at least 
the first morning after surgery. A previous study on horses with signs of acute colic 
showed significantly lower concentrations of 5-HT compared to healthy ones [19]. 
However, this earlier study focused on serum concentration of 5-HT used the ELISA 
method of analysis. This situation complicates the comparison of these results with 
the current ones. In contrast to these achievements, Delesalle et al. [11] indicated 
an increase in plasma concentrations of 5-HT, measured by HPLC, in a small group 
of horses undergoing small bowel surgery. In addition to the analytical differences 
between these studies, there are multiple possible physiological and pathological 
explanations for variations in the results obtained.
2.2 Vascular dysfunctions: Laminitis
The GI flora produces relatively high concentrations of dietary amines by 
fermenting the consumed amino acids [44, 45]. It is thought that the link between 
the GI system and the equine foot occurs through dietary amines.
The bacteria responsible for the fermentation of carbohydrates produce enzymes 
(amino acid decarboxylase) that convert free amino acids to monoamines. Then, 
the fermentation of large amounts of carbohydrates in the large intestine is associ-
ated with a greater number of Gram-positive bacteria (Streptococci and Lactobacilli) 
and elevated production of dietary amines [12]. These bacteria increase in the 
production of lactate, which is responsible for the decrease in intraluminal pH caus-
ing death of Gram-negative bacteria and therefore an increase in endotoxin release 
(lipopolysaccharide, LPS). Tryptamine is the most potent amine in the cecum. It 
causes vasoconstriction both in vitro and in vivo through direct activation of seroto-
nergic receptors and 5-HT displacement of PLTs. Monoamines found in the horse’s 
cecum could potentially induce hemodynamic disturbances in the hoof resulting in 
lamellar ischemia and therefore laminitis [46–50]. Besides, these monoamines pres-
ent in the cecum can also be detected at much lower concentrations in blood plasma.
Leukocytes can be indirectly activated by PLTs and mainly by LPS. Therefore, 
endotoxin may contribute to the initiation of early inflammatory changes observed 
in experimental models of acute laminitis [13]. This may occur because the amines 
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are able to mimic and potentiate the effects of the biogenic amines (5-HT, epi-
nephrine, norepinephrine, and dopamine) in the circulation. Gut-derived amines 
mimic the actions of the endogenous biogenic amines by displacing 5-HT from PLTs 
or norepinephrine from sympathetic nerve ending or by directly activating the 
receptors for these amines on the vasculature [49]. The potentiation of the action 
of endogenous amines is produced by two processes: inhibition of absorption in 
endothelial cells and PLTs [47, 48] or by competition between amines derived from 
the intestines and endogenous amines by the metabolism of the enzyme amine 
oxidase [12, 47, 48].
Dietary amines are similar to substances normally produced by the body, 
including catecholamines and 5-HT. Since 5-HT is a potent vasoconstrictor that is 
mainly stored in PLTs, it helps to maintain low plasma concentrations that reduce its 
effects. Bailey et al. [46] reported that the absorption of 5-HT by PLTs is a saturable 
process in horses. The most efficient way to work is at substrate concentrations 
below the micromole. The noncompetitive inhibition of 5-HT absorption by other 
natural monoamines may result in increased plasma concentrations of 5-HT and 
endotoxin release. The amines present in the diet inhibit the uptake of 5-HT from 
the PLTs. As a result, plasma concentration of 5-HT would increase above the level 
at which digital vasoconstriction occurs [44, 51]. However, other peripheral blood 
vessels are unaffected, since digital vessels are much more sensitive to the vaso-
constriction effects of 5-HT [52, 53]. Dietary amines can also cause digital vaso-
constriction directly [49]. The overall result is the digital ischemia and subsequent 
reperfusion, which could lead to the activation of metalloproteinases.
Endotoxins act as a mechanism that triggers laminitis. These substances activate 
the coagulation cascade directly through the Hageman factor (factor XII, in the 
intrinsic coagulation pathway). They are called the contact factor because the 
activation occurs by contact with nonendothelial and foreign surfaces. In addition, 
endotoxins are the initial stage of intrinsic plasma coagulation. They also cause 
damage to endothelial cells and favor the addition of PLTs, thereby establishing a 
blood profile compatible with disseminated intravascular coagulation (DIC). As a 
result, peripheral vasoconstriction initially results in decreased capillary perfusion 
of the hoof with some degree of ischemia [47, 48].
The aggregation of PLTs and the formation of microthrombi in the capillaries of 
the hull contribute to maintain vascular occlusion ischemia. In addition, a potent 
vasoconstrictor such as thromboxane A2 is released from PLTs, which adds to 
increase the process. At the same time, the inflammatory response begins with the 
release of autacoids such as histamine, 5-HT, bradykinin, prostanoids, leukotrienes, 
and interleukin 1. Histamine plays a very important role in acute inflammation. 
It has a vasodilatory action on arterioles, but the role in inflammation is more 
important, since it improves the action of other mediators such as histamine and 
bradykinin. This results in arteriolar dilation, increased capillary permeability, and 
hyperalgesia. Leukotriene B4 is also involved in the passage of leukocytes to inflam-
matory exudate [16].
The relationship between the appearance of digital hypoperfusion and increases 
in plasma concentration of 5-HT is consistent. This is because PLTs-derived media-
tors are associated with LPS-induced laminitis. These experimental data support 
the use of antiPLT therapy in the prevention of laminitis related to endotoxemic 
diseases [16].
2.3 Endocrine diseases: pituitary pars intermedia dysfunction
Pituitary pars intermedia dysfunction (PPID) or Cushing’s disease is character-
ized by hypertrophy and hyperplasia of the Pituitary Pars Intermedia and is argued 
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to be due to a reduction in dopamine synthesis or degeneration of periventricular 
pituitary dopaminergic neurons [54]. PPID is more frequent in adult horses and 
result of a progressive loss of the neurotransmitter at central and peripheral level as 
result of the degeneration of the pineal gland [15].
The role of 5-HT in the regulation of the PPID it is not clear. Treatment of PPID 
in horse includes 5-HT antagonists [55], such as cyproheptadine. Antagonist of 
5-HT is potent secretagogue of ACTH in pituitary rat tissue, and it was used effec-
tively in human Cushing’s disease. Cyproheptadine decreases the 5-HT-induced 
stimulation to the pituitary pars intermedia, the synthesis of pro-opiomelano-
cortin (POMC), and finally, ACTH secretion. Cyproheptadine (0.25–0.5 mg/kg 
PO, SID, or BID) was used for the treatment of PPID result in an improvement in 
clinical status and normalization of laboratory parameters within 1–2 months of 
treatment initiation, being effective in 28–60% of cases [56]. However, similar 
improvements were achieved with improved nutrition, preventive care, and 
management alone [57].
Additionally, Bailey et al. [46] measured peripheral plasma concentrations of 
5-HT in summer, autumn, winter, and spring in clinically normal ponies and those 
predisposed to laminitis, and no significant differences were observed. Although 
light/dark differences were not investigated in the latter work, nycthemeral 
increases in serum 5-HT in the healthy, athletic horse have been reported [20]. 
Later, Haritou et al. [15] reported seasonal changes in circadian peripheral plasma 
concentrations of melatonin, 5-HT, dopamine, and cortisol in aged horses with 
PPID. Six horses and ponies with PPID were matched with six controls to test the 
hypothesis that aged horse responds differently to changes in season because of 
deficiency in melatonin production. They also examined the link between the 
presence or absence of the clinical signs of PPID and peripheral plasma concen-
tration of 5-HT, dopamine, and cortisol. Results showed that the 24-h pattern of 
plasma melatonin concentrations during the four seasons of the year was similar in 
both groups, indicating that impaired melatonin output is unlikely to play a role in 
PPID. However, 5-HT profiles were affected by season, with lower 5-HT detected 
in PPID horses in the summer and winter. Although the reasons for this reduc-
tion remain unknown, enhanced conversion of 5-HT to melatonin could account, 
at least in part, for the lowered circulating level. The total amount of dopamine 
released was dependent on season and markedly lower in PPID horses versus 
controls. These results implicate both serotonin and dopamine in the pathogenesis 
of the disease [15].
2.4 Behavioral alterations: stereotypes
Most frequently observed stereotypies in domestic horses are crib biting, weav-
ing, box walking, wind sucking, and wood chewing. However, there is no scientific 
consensus as to whether wood chewing is definitely a stereotypy [58]. More 
recently, some morphological variations of these stereotypic activities have also 
been identified as equine stereotypies, such as licking the environment, lip licking, 
sham chewing or teeth grinding, self-biting, and rubbing self, as well as locomotion 
stereotypies, including pawing, tail swishing, door kicking or box kicking, and head 
tossing/nodding [59]. The most common forms of equine stereotypies are within 
two general categories, oral and locomotion stereotypic behaviors.
The neurobiological consequences of equine stereotypies focus on neurotrans-
mitter systems, specifically the serotonergic and dopaminergic pathways [59, 60]. 
5-HT is implicated in the underlying pathology of stereotypies. Indeed, Lebelt et al. 
[61] found a trend for lower basal 5-HT levels in crib-biting compared to nonstereo-
typic horses, suggesting that the serotonergic system of crib-biters may differ from 
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that of noncrib biting horses (mean 201.5 vs. 414.3 nmol/l). The precise role of 5-HT 
in the development or maintenance of the behavior remains unclear however, and 
the results obtained by these authors have yet to be confirmed or refuted through 
additional experimental studies of the serotonergic system in crib-biting horses.
However, blood levels of 5-HT in horses with weaving is more than triple 
compared to healthy horses. Thus, 5-HT is recognized as the “happiness hormone” 
or “pleasure hormone” [62]. It can be assumed that during the demonstration of 
stereotypical disorder, horses are “happy,” and that repetitive disturbance is a means 
of increasing 5-HT levels in the blood and therefore the feeling of comfort [63].
Serotonin reuptake inhibitors (SRI) are a type of drug which acts as a reuptake 
inhibitor of the neurotransmitter serotonin (5-hydroxytryptamine (5-HT)) by 
blocking the action of the serotonin transporter (SERT). This in turn leads to 
increased extracellular concentrations of serotonin and, therefore, an increase in 
serotonergic neurotransmission. Although administration of SRIs drugs has been 
associated with the reduction of stereotypies, it was dubious if such medications 
decreased stereotypic behaviors due to general sedative effects or selectively influ-
enced stereotypic behavior. These uncertainties were due to general sedative effects 
or selective influence on the type of behavior. As previously expressed, the specific 
role of 5-HT in the development or maintenance of behavior remains uncertain  
[60, 61, 64, 65], and further studies are needed to provide a more accurate interpre-
tation of stereotypes.
Pharmacological preparations containing TRP are marketed worldwide as 
relaxing agents for treating excitable horses. The few studies in which TRP has been 
administered to horses suggest that low doses cause mild excitation. However, high 
doses reduce endurance capacity and cause acute hemolytic anemia when given 
orally due to the presence of a toxic metabolite in the intestine [65, 66]. Despite 
questions about its effectiveness, TRP is marketed as an equine sedative and is 
related to sedation, inhibition of aggression, fear, and stress.
Because TRP competes with other amino acids to bind to protein transport and 
cross the blood-brain barrier, researchers are now using a ratio of TRP with other 
large neutral amino acids (ANNALs) to estimate the production of 5-HT in the CNS 
[67]. Besides, previous researchers showed that the age, breed, and gender modify 
the response of serotoninergic system due to changes in dietary TRP [17, 68]. While 
all of these factors may play a role in the permeability of the blood-brain barrier, the 
effectiveness of supplemental TRP on 5-HT biosynthesis, it is also worth consider-
ing that these types of treatments may be most effective in horses with dysfunction-
ing serotoninergic system.
Although the safety of TRP doses should be confirmed, there is no evidence 
to suggest that a single dose is an effective analgesic in horses. In fact, given that 
TRP continues to be used as a tranquilizer, there is an urgent need for research to 
confirm its efficacy and establish a range of safe therapeutic doses. In the mean-
time, available data suggest that it would be unwise to rely on the TRP to calm the 
excitable horse. Instead, more efforts should be made to identify the underlying 
causes of excitability and explore other more appropriate nonpharmacological 
solutions. Indeed, when evaluating the use of calming supplements or drugs, it is 
important to consider the welfare of the horse. While calmative compounds may be 
beneficial in alleviating short-term stress and anxiety, the cause of such emotions 
should also be evaluated. Horses kept in unnatural environments, managed poorly, 
or asked to perform beyond their level of training may show signs of stress and 
anxiety. Chronic health issues, such as ulcers or lameness, may also be the culprit. 
Sedative drugs and supplements are often utilized to limit unwanted behaviors 
such as spooking, bolting, rearing, or bucking. Looking into the potential causes of 
unwanted behaviors should be the first step before owners turn to calming drugs or 
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supplements. Providing more training, turnout time, or treatment for an underly-
ing disease or condition could result in a more sustainable way to reduce a horse’s 
unwanted behaviors and could improve welfare for the animal [65].
Equine self-mutilation syndrome (ESMS) includes glancing or biting at the flank 
or pectoral areas, bucking, kicking, vocalizing, rubbing, spinning, or rolling. Eight 
flank-biting horses with ESMS were enrolled for a behavioral study, and the effects 
of drugs that either stimulate or inhibit central opioid, dopamine, norepineph-
rine, and 5-HT neurotransmitter systems were reported. Behaviors were recorded 
hourly during the study and were compared with those of a saline control baseline 
to determine whether there were significant differences among the treatments. 
The suppression of ESMS activities with Buspirone (0.5 mg/kg) suggests a role for 
serotonergic modulation of the behavior. However, the clomipramine, a preferential 
5-HT reuptake blocker, does not produce any significant effect on ESMS behavior in 
horses [69].
Horses with compulsive disorder may help the fluoxetine at dose of  
0.25–0.5 mg/kg/day PO. Fluxetine is a selective serotonin reuptake inhibitor (SSRI) 
that increases 5-HT levels within CNS by preventing the reuptake of 5-HT at level 
of the presynaptic neuron. This allows 5-HT to accumulate in the synaptic cleft and 
affect the postsynaptic neuron. While no cases of fluoxetine-induced colic have 
been reported in horses being treated for behavior problems and because there are 
many 5-HT receptors in the gut, it is advisable to begin administering the drug at 
the lowest dose and increase it gradually in horses that do not improve and have not 
exhibited adverse effects [70].
The ability to train and control horses is an important behavioral trait for the 
handling and training of animals. Hori et al. [71] inform that horses carrying allele 
A located at c. 709G > A had a lower capacity to be handled. These results provide 
the first evidence that a polymorphism in a 5-HT-related gene may affect the man-
agement of horses with a partially different sex-related effect.
2.5 Recurrent airway obstruction
Based on the results reported in humans, in which PLTs contribute to the patho-
genesis of allergic airway disease, Hammon et al. [14] compared PLT aggregation 
induced by the activating factor PLTs (PAF), thromboxane (Tx), plasma Tx, and 
5-hydroxytryptamine (5-HT) production in ponies with recurrent airway obstruc-
tion (RAO) before and after antigen exposure. Plasma 5-HT was significantly higher 
in ponies with RAO but did not increase more by exposure to the antigen. There 
were also no differences between the aggregation of PLTs induced by PAF or the 
production of Tx or plasma Tx before or after exposure. These evidences suggest 
that there may be a difference between 5-HT uptake of PLTs in RAO and normal 
ponies. However, they do not provide evidence of PLTs activation after exposure to 
the antigen. This bronchoconstriction can be mediated by 5-HT. However, the effect 
or pathway of 5-HT may be deactivated during the development of small airway 
disease [72].
2.6 Central fatigue
Accordingly, the synthesis and metabolism of 5-HT in the CNS increase in 
response to exercise [73]. Increased 5-HT concentration in the brain is associated 
with central fatigue markers, such as decreased motivation, lethargy, fatigue, or 
loss of motor coordination [74].
It has been shown that nutritional status can alter cerebral neurochemistry, 
especially carbohydrates and 5-HT [75]. Therefore, it has been hypothesized that 
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infusion of TRP may increase the ratio of fTrp (free TRP) and fTrp to BCAA while 
decreasing the resistance of endurance horses to treadmill. Therefore, central 
fatigue may limit resistance in horses, and by manipulating fTrp and BCAA, 
exercise capacity could be altered in a predictable way [76]. However, TRP infu-
sion results are consistent with the central fatigue hypothesis where an increase in 
plasma fTrp concentration is related to the early onset of fatigue during prolonged 
exercise [77]. Piccione et al. [20] reported that if exercise is performed at the 
time of the rhythmic acrophase of the TRP (18:45, 18:16), it is likely that exercise 
performed at the time of the acrophase of the TRP rhythm (18:45, 18:16) affects 
the onset of physiological fatigue, thus turning on the body’s exercise adaptation 
mechanisms in order to maintain better physical performance.
2.7 Other conditions
Virus of Borna’s disease (BDV) can enter into the brain and infect neurons, 
often the limbic system. It can also remain active for long periods of time in the 
CNS without generating neuronal lysis. The BDV virus is unique in the order of 
mononegavirals because it replicates in the cell nucleus. Alterations include falling, 
tremor, abnormal posture, hyperactivity or hypoactivity, increased aggression, and 
paralysis. In some rodent species, BDV can cause mild or asymptomatic symptoms, 
while in other animal species such as horses, it can cause severe CNS symptoms 
that often lead to death. In humans, a common treatment for psychiatric illnesses 
such as depression or anxiety disorders is the use of SSRIs. The function of these 
drugs is to increase extracellular 5-HT. Interestingly, there are viruses that can exert 
the opposite action and reduce levels of 5-HT and therefore theoretically have an 
opposite effect to SSRI [78].
Equine hepatic encephalopathy is caused by direct damage to the liver or by 
toxins derived from the intestine that overwhelm or evade this organ. These toxins 
act on the CNS, giving rise to signs of encephalopathy. Secondary hepatic encepha-
lopathy in horses occurs more often than liver failure. This may be due to megalo-
cytic liver disease caused by ingestion of plants containing pyrrolizidine alkaloid 
(Senecio, Crotalaria and Amsinckia), Theiler’s or Tyzzer’s disease, cholangiohepati-
tis, chronic active hepatitis, liver neoplasia, toxic liver disease, and portosystemic 
shunts [79]. Because the liver is incapacitated, normal detoxification activities 
cannot be performed in all these conditions. Therefore, toxins derived from IG 
enter the CNS through the bloodstream.
In horses, hyperammonemia has been linked to clinical signs of encephalopathy 
without evidence of liver disease, which promotes the formation of Alzheimer’s 
cells II [80]. It is also suggested that alteration of amino acid metabolism with 
upward regulation of aromatic amino acids and downward regulation of BCAA 
lead to direct neuronal inhibition secondary to effects on CNS. Alteration of gamma 
aminobutyric acid (GABA) and glutamate during liver failure plays an important 
role in the physiopathology of hepatic encephalopathy. Liver impairment leads to an 
increase in substances similar to endogenous benzodiazepines that inhibit neuronal 
excitation. Therefore, the most likely scenario is that there are multiple mechanisms 
working in synergy with each other to create signs of encephalopathy.
3. Conclusions
Serotonin is a neurotransmitter associated with important physiological, diges-
tive, and vascular functions of the central nervous system. This review describes 
the involvement of serotonin in the most common pathological processes of equine 
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